Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Advanced Medicine, Analytical Science, Bioprocessing - Upstream & Downstream, Bioprocessing - Single Use Systems

Advanced Medicine: Replicating the mAb Success Story

The rise of monoclonal antibodies (and other important biopharmaceuticals) has taught the industry much in terms of how to successfully manipulate and manufacture living cells to achieve the desired yields and properties. But the next stage of evolution for drug manufacturers is far more complicated and tends to require the production of viral vectors; relatively few cell and gene therapies have been commercialized so far – and prices are high, reflecting the increased development and manufacturing challenges. There is a long way to go before the industry can say it has truly optimized the processes for bringing these advanced therapies to market. Clive Glover, Director, Cell and Gene Therapy, and Rene Gantier, Director Biotech Process Research & Development, both from Pall, review the progress so far and assess how manufacturing can be improved for viral vectors.

What cell and gene therapy milestones have we passed in recent years?

Clive Glover: Well, there have been exciting approvals and some amazing results coming from the clinic. One key milestone that stands out to me in particular, is the deal signed between Novartis and the University of Pennsylvania in 2013 because it really kicked off the CAR-T field and put advanced medicine in the spotlight for big pharma and investors. And then we saw the beginnings of companies like Kite Pharma, which was purchased by Gilead, and Juno Therapeutics, later purchased by Celgene. When it comes to the gene therapy side, there are many small gene therapy companies that have been struggling along for years, but 2013 saw investors really stand up and take notice of these, too. Today, there is a phenomenal amount of investment going into both cell therapy manufacturing and gene therapy manufacturing. According to estimates, around $22 billion in capital funding was committed to the industry in 2018, which is 30 percent increase on the funding received in 2017.

Rene Gantier: This is a big moment for the sector, especially for gene therapy, which has been waiting a long time. The money pouring into the field means that companies can start to tackle the challenges associated with industrialization and figure out how we safely bring these therapies to as many patients as possible.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Stephanie Sutton

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent seven years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register